Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Active not recruiting 4Completed 2Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Colorectal Neoplasms 1Cholangiocarcinoma 1Bile Duct Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × quemliclustat × 1 year × Clear all
NCT04104672 2026-06-02

ARC-8

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
196 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05329766 2026-06-02

EDGE-Gastric

Arcus Biosciences, Inc.

Phase 2 Active not recruiting
332 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06608927 2026-06-02

PRISM-1

Arcus Biosciences, Inc.

Phase 3 Active not recruiting
610 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05676931 2026-06-01

EDGE-Lung

Gilead Sciences

Phase 2 Active not recruiting
400 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Big Ten Cancer Research Consortium

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed
227 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡